Navigation Links
Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Date:11/16/2011

SAN MATEO, Calif., Nov. 16, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced top-line data from its recently completed Phase I clinical trial evaluating the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide in patients with chronic heart failure. Nile is developing cenderitide as a 90-day outpatient treatment for heart failure patients following admission for acutely decompensated heart failure (ADHF), referred to as the "post-acute" treatment period.

The Phase I clinical trial was designed to understand the doses required to achieve pre-determined plasma levels of cenderitide when delivered through a subcutaneous infusion pump. The target cenderitide plasma levels were based on Nile's previous Phase 2 clinical trials in which cenderitide was delivered through continuous intravenous infusion. In Part A of the trial, 12 patients received two subcutaneous bolus injections of cenderitide.  In Part B of the trial, 34 patients received a 24-hour continuous subcutaneous infusion of either of two fixed doses of cenderitide or placebo. In Part C, 12 patients received a 24-hour continuous subcutaneous infusion of either a weight-based dose of cenderitide, or placebo. All infusions were delivered through subcutaneous pump technology of Medtronic, Inc. pursuant to the parties' February 2011 development collaboration agreement.

The top line results from the Phase 1 trial are as follows:

  • The primary end-point was met – cenderitide achieved target PK levels when delivered through Medtronic's subcutaneous pump technology;
  • 24 hour subcutaneous delivery of ceneritide through Medtronic's pump technology was well-tolerated, with no injection site irritation;
  • Subcutaneously delivered cenderitide has an acc
    '/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Nile Therapeutics Reports 2011 Third Quarter Financial Results
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Orexigen® Therapeutics Reports Third Quarter Financial Results
4. Silence Therapeutics Provides Corporate and Development Update
5. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
6. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
7. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
8. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
9. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
10. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
11. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... RICHMOND, Calif., July 23, 2014  Sangamo BioSciences, Inc. ... quarter 2014 financial results and accomplishments. ... reported a consolidated net loss of $7.0 million, or ... $5.5 million, or $0.10 per share, for the same ... Company had cash, cash equivalents, marketable securities and interest ...
(Date:7/23/2014)... -- Think Drinks are a neuroscience-backed drink regimen developed ... are the first functional focus beverage to give users ... to the temporary fix associated with energy drinks. truBrain ... 2014, with hopes to raise $50,000 over the course ... http://photos.prnewswire.com/prnh/20140723/129697 Think Drinks were designed ...
(Date:7/23/2014)... , July 23, 2014  Having the right people ... vital to accelerating business growth and achieving clinical and ... Association (AHA) Leadership Summit, July 20-22, 2014, in ... of hospital executives and healthcare experts discussing how partnerships ... Carrocino , President & Chief Executive Officer of Cape ...
(Date:7/23/2014)... 23, 2014 DuPont Pioneer announced today ... vice president of Agricultural Biotechnology (ABT), effective July 21, ... served most recently as president, chief executive officer and ... leadership in the seed and crop protection industry to ... E. Schickler , president of DuPont Pioneer. “I am ...
Breaking Biology Technology:Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3
... Partners announced,today that it has initiated coverage on ... promising drug development pipeline for treating a,variety of ... on two,drug development programs; the first is MN-221 ... estimated 2,000,000 visits to the emergency room,a year ...
... Third Party Administrators,Alliance (TPAA) announced today the appointment ... the nation,s first alliance of third party,administrators and ... to its members., Oelschlager brings hands-on experience ... role, assets he believes will further the,organization,s reach ...
... PRXL ), a leading global biopharmaceutical services,organization, ... Goldberg, M.D.,to Chief Operating Officer (COO). Dr. Goldberg ... Perceptive Informatics at,PAREXEL. He will continue to oversee ... von Rickenbach, Chairman and Chief Executive Officer of ...
Cached Biology Technology:Vista Partners Initiates Coverage on MediciNova Inc. (Nasdaq: MNOV) 2The TPAA Names Mark Oelschlager President 2PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer 2PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer 3PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer 4
(Date:7/24/2014)... researchers led by the University of York has carried ... the Western Indian Ocean. , The results, reported ... a revolution in the management of marine protected areas, ... 11,000 km in the region now under local ... of the seas and coasts designed to protect wildlife ...
(Date:7/24/2014)... from Singapore have developed Asia,s first genetic test for ... affects the cornea called corneal stromal dystrophy which can ... Called the POLARIS TGFBI (Transforming Growth Factor beta Induced) ... the diagnosis and management of patients with corneal stromal ... TGFBI mutation who may also be at risk of ...
(Date:7/23/2014)... new study of identical twins has found that early ... study, in the journal Child Development , was ... King,s College London. , "Since reading is an ability ... reading instruction," according to Stuart J. Ritchie, research fellow ... the study. "Early remediation of reading problems might aid ...
Breaking Biology News(10 mins):Western Indian Ocean communities play vital role in conservation 2Singapore team develops Asia's first genetic test that can prevent corneal blindness 2Singapore team develops Asia's first genetic test that can prevent corneal blindness 3Stronger early reading skills predict higher intelligence later 2
... revealed a previously unknown mechanism in the body which ... responses and control of blood pressure, pain and appetite. ... help fight health problems connected with these functions in ... and University College London found that lactate essentially ...
... New York, NYFebruary 10, 2014In a study published ... team led by Ken Shepard, professor of electrical ... Lars Dietrich, assistant professor of biological sciences at ... the basis of modern computers and communications devices, ...
... change unfolds over the next century, plants and animals will ... climate. A new study provides an innovative global map of ... up with a changing climate. The findings appear in the ... a UC Santa Barbara National Center for Ecological Analysis and ...
Cached Biology News:New research sheds light on how the body regulates fundamental neuro-hormone 2Chips that listen to bacteria 2Maps show expected redistribution of global species due to climate change 2Maps show expected redistribution of global species due to climate change 3
... MasterAmp™ Taq DNA Polymerase is a ... aquaticus. Having optimal activity at temperatures ... thermostable enzyme used for PCR and ... purpose. The enzyme has an intrinsic ...
... 4100 high pressure dual piston pump and the ... and utra low drift. The WaveQuest ... detection and provides superior stability. Hence ... and for monitoring to the highest of sensitivities. ...
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
... This CLS number ... number, created to easily ... If showing no availability ... the old Sigma-Aldrich number ...
Biology Products: